Clinically, upregulated TRIM29 leads to tumor progression or poor prognosis in gastric cancer [13], prostate cancer [14], pancreatic adenocarcinoma [15], lung cancer [16, 17], nasopharyngeal carcinoma [18], as well as bladder cancer [19]. Here, TRIM29 is linked to urinary bladder cancer.